# NCT04898634 (NCT04898634)

> A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: pasritamig
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04898634
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Prostatic Neoplasms
- Interventions: JNJ-78278343
- Enrollment: 216
- Primary outcome: Part 1 and 2: Number of Participants With Adverse Events (AEs)
- Primary outcome: Part 1 and 2: Number of Participants With AEs by Severity
- Primary outcome: Part 1: Number of Participants With Dose-Limiting Toxicity (DLT)

## Indexed commentary on NCT04898634 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct04898634
